Viewing Study NCT03646851


Ignite Creation Date: 2025-12-24 @ 11:52 PM
Ignite Modification Date: 2026-01-05 @ 1:06 PM
Study NCT ID: NCT03646851
Status: COMPLETED
Last Update Posted: 2025-11-19
First Post: 2018-08-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Aspergillus and Chronic Obstructive Pulmonary Disease Evolution
Sponsor: Centre Hospitalier Universitaire, Amiens
Organization:

Study Overview

Official Title: Impact of Aspergillus on Chronic Obstructive Pulmonary Disease Evolution
Status: COMPLETED
Status Verified Date: 2025-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: AspergBPCO
Brief Summary: This is a prospective multicenter cohort study which includes all consecutive COPD patients who come for a visit in one the participating pneumologist. They will have to do a sputum and to complete some questionnaries. Questionnaries will be redone by phone after 1 and 3 months and during the visit after 6 months. We will correlate aspergillus presence in sputum with quality of life (QoL), and COPD symptoms evaluated by questionnaires.
Detailed Description: Aspergillosis disease is a growing problem. These diseases are not yet uncommon in chronic obstructive pulmonary disease patients. (COPD).

Aspergillosis disease are very difficult to be diagnosed or treated. Isolation of aspergillus in sputum of patients is not always responsible of a real disease. Need of treatment is discussed. That is why, we will conduct a prospective cohort study to evaluate aspergillus rate in respiratory samples of COPD patients (GOLD stage III or IV)

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: